Mrs Towanda Ann Miller, LPN | |
Bldg 301 Andrews Ave, Lyster Army Health Clinic, Fort Rucker, AR 36362-5333 | |
(334) 255-7341 | |
(334) 255-7368 |
Full Name | Mrs Towanda Ann Miller |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | Bldg 301 Andrews Ave, Fort Rucker, Arkansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073895876 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 2-045271 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Towanda Ann Miller, LPN Bldg 301 Andrews Ave, Lyster Army Health Clinic, Fort Rucker, AR 36362-5333 Ph: (334) 255-7341 | Mrs Towanda Ann Miller, LPN Bldg 301 Andrews Ave, Lyster Army Health Clinic, Fort Rucker, AR 36362-5333 Ph: (334) 255-7341 |
News Archive
A meta-analysis of dozens of studies of traditional Chinese medicine and other nonpharmacological interventions meant to improve patients' quality of life affirms that these approaches, on the whole, help alleviate depression, fatigue, pain, anxiety, insomnia and gastrointestinal problems in Chinese cancer patients.
Health care β and how much it costs β is scary. But you're not alone with this stuff, and knowledge is power. "An Arm and a Leg" is a podcast about these issues, and its second season is co-produced by KHN.
Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions.
Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers.
› Verified 7 days ago